insights_auto
Why is ALTME down 4.50%?
Dive Deeperchevron_right
ALTME:EPA
TME Pharma NV
€0.11
arrow_downward
-4.50%(-0.0050) 1D
Oct 20, 4:16:54 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALTME...
Open
€0.11
High
€0.11
Low
€0.10
Mkt. cap
10.16M
Avg. vol.
1.85M
Volume
127.61K
52-wk high
€0.17
52-wk low
€0.05
EPS
-€0.03
No. of employees
0
Open
€0.11
High
€0.11
Low
€0.10
Mkt. cap
10.16M
Avg. vol.
1.85M
Volume
127.61K
52-wk high
€0.17
52-wk low
€0.05
EPS
-€0.03
No. of employees
0
News stories
From web sources and news partners
bloomingbit
·
6 minutes ago
U.S. Stocks Turn Higher; Nasdaq Rises 0.52%
ChartMill
·
33 minutes ago
S&P 500 Gap-Down Stocks Fall in October 20, 2026 Session
TradingView
·
1 hour ago
Chip Stocks Resume Declines
Yahoo Finance
·
2 hours ago
DOW Gains on Projects & Self-Help Actions Amid Demand and Cost Woes
Profile
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
About TME Pharma NV